secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K/A
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001437749-23-030460
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan
--------------------------------------------------------------------------------

- Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.
- PH80 is a non-systemic, hormone-free pherine nasal spray for acute treatment of moderate-to-severe hot flashes due to menopause.
- Purchase price credited against signing fee if definitive license agreement reached.
- Neither party obligated to enter definitive agreement; negotiations may be terminated after exclusive period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/0001437749-23-030460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/vtgn20231106_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer